NZ724057A - Treatment of intrahepatic cholestatic diseases - Google Patents
Treatment of intrahepatic cholestatic diseasesInfo
- Publication number
- NZ724057A NZ724057A NZ724057A NZ72405715A NZ724057A NZ 724057 A NZ724057 A NZ 724057A NZ 724057 A NZ724057 A NZ 724057A NZ 72405715 A NZ72405715 A NZ 72405715A NZ 724057 A NZ724057 A NZ 724057A
- Authority
- NZ
- New Zealand
- Prior art keywords
- treatment
- cholestatic diseases
- intrahepatic cholestatic
- intrahepatic
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968037P | 2014-03-20 | 2014-03-20 | |
| PCT/US2015/021502 WO2015143178A1 (en) | 2014-03-20 | 2015-03-19 | Treatment of intrahepatic cholestatic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ724057A true NZ724057A (en) | 2018-09-28 |
Family
ID=52808186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ724057A NZ724057A (en) | 2014-03-20 | 2015-03-19 | Treatment of intrahepatic cholestatic diseases |
Country Status (32)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0920170A2 (pt) | 2008-10-17 | 2016-06-21 | Metabolex Inc | métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método. |
| US10272058B2 (en) * | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| CN106163508A (zh) | 2014-04-11 | 2016-11-23 | 西玛贝医药公司 | Nafld和nash的治疗 |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| UA125600C2 (uk) * | 2017-09-26 | 2022-04-27 | Сімабей Терапьютікс, Інк. | Лікування холестатичного свербежу |
| MX2021005725A (es) * | 2018-11-16 | 2021-07-21 | Cymabay Therapeutics Inc | Tratamiento de la obesidad y sus complicaciones. |
| CA3148602A1 (en) | 2019-08-02 | 2021-02-11 | Acelot, Inc. | Small molecule drugs and related methods for treatment of diseases related to tdp-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation |
| US20210145775A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of intestinal barrier dysfunction and associated diseases |
| US20210145774A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of alcoholic liver disease |
| US20220241228A1 (en) | 2021-02-01 | 2022-08-04 | Cymabay Therapeutics, Inc. | Treatment of cholangiopathies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| EP0813539B1 (en) | 1995-03-06 | 2006-05-24 | Isis Pharmaceuticals, Inc. | Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom |
| WO1997030067A1 (en) | 1996-02-14 | 1997-08-21 | Isis Pharmaceuticals, Inc. | Sugar-modified gapped oligonucleotides |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US7981915B2 (en) * | 2003-04-30 | 2011-07-19 | Beth Israel Deaconess Medical Center | Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene |
| SG145752A1 (en) | 2003-09-19 | 2008-09-29 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| SI1725234T1 (sl) | 2004-03-05 | 2013-04-30 | The Trustees Of The University Of Pennsylvania | Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov |
| JO3006B1 (ar) * | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| BRPI0920170A2 (pt) | 2008-10-17 | 2016-06-21 | Metabolex Inc | métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método. |
| SG183529A1 (en) | 2010-03-30 | 2012-10-30 | Novartis Ag | Uses of dgat1 inhibitors |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AU2014353246A1 (en) | 2013-11-20 | 2016-06-16 | Cymabay Therapeutics, Inc. | Treatment of homozygous familial hypercholesterolemia |
| US20160279085A1 (en) | 2013-11-20 | 2016-09-29 | Cymabay Therapeutics, Inc. | Treatment of Severe Hyperlipidemia |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| CN106163508A (zh) | 2014-04-11 | 2016-11-23 | 西玛贝医药公司 | Nafld和nash的治疗 |
| HK1231380A1 (zh) | 2014-06-26 | 2017-12-22 | Cymabay Therapeutics, Inc. | 严重高甘油三酯血症的治疗 |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| UA125600C2 (uk) | 2017-09-26 | 2022-04-27 | Сімабей Терапьютікс, Інк. | Лікування холестатичного свербежу |
| MX2021005725A (es) | 2018-11-16 | 2021-07-21 | Cymabay Therapeutics Inc | Tratamiento de la obesidad y sus complicaciones. |
| EA202191379A1 (ru) | 2018-11-16 | 2021-08-06 | Саймабэй Терапьютикс, Инк. | Комбинированное лечение nafld и nash |
-
2015
- 2015-03-19 LT LTEP15714132.6T patent/LT3119384T/lt unknown
- 2015-03-19 CN CN201580014506.0A patent/CN106102734B/zh active Active
- 2015-03-19 EP EP15714132.6A patent/EP3119384B1/en active Active
- 2015-03-19 WO PCT/US2015/021502 patent/WO2015143178A1/en not_active Ceased
- 2015-03-19 US US14/663,027 patent/US9486428B2/en active Active
- 2015-03-19 NZ NZ724057A patent/NZ724057A/en unknown
- 2015-03-19 SM SM20180690T patent/SMT201800690T1/it unknown
- 2015-03-19 EA EA201691887A patent/EA032358B1/ru active IP Right Revival
- 2015-03-19 BR BR112016020260A patent/BR112016020260A8/pt not_active Application Discontinuation
- 2015-03-19 MX MX2016012203A patent/MX367478B/es active IP Right Grant
- 2015-03-19 UA UAA201609525A patent/UA120756C2/uk unknown
- 2015-03-19 RS RS20181363A patent/RS57970B1/sr unknown
- 2015-03-19 DK DK15714132.6T patent/DK3119384T3/en active
- 2015-03-19 HU HUE15714132A patent/HUE041733T2/hu unknown
- 2015-03-19 SI SI201530455T patent/SI3119384T1/sl unknown
- 2015-03-19 HR HRP20181914TT patent/HRP20181914T1/hr unknown
- 2015-03-19 AU AU2015231232A patent/AU2015231232B2/en active Active
- 2015-03-19 KR KR1020167025636A patent/KR102000332B1/ko active Active
- 2015-03-19 PL PL15714132T patent/PL3119384T3/pl unknown
- 2015-03-19 JP JP2017501116A patent/JP6568577B2/ja active Active
- 2015-03-19 CA CA2941401A patent/CA2941401C/en active Active
- 2015-03-19 ES ES15714132T patent/ES2701094T3/es active Active
- 2015-03-19 PT PT15714132T patent/PT3119384T/pt unknown
-
2016
- 2016-08-31 ZA ZA2016/06043A patent/ZA201606043B/en unknown
- 2016-09-08 PH PH12016501769A patent/PH12016501769A1/en unknown
- 2016-09-15 CL CL2016002338A patent/CL2016002338A1/es unknown
- 2016-09-19 IL IL247920A patent/IL247920B/en active IP Right Grant
- 2016-09-21 US US15/271,460 patent/US9808436B2/en active Active
-
2017
- 2017-09-29 US US15/720,849 patent/US10220011B2/en active Active
-
2018
- 2018-11-28 CY CY181101264T patent/CY1120927T1/el unknown
- 2018-12-17 US US16/222,325 patent/US10828273B2/en active Active
-
2020
- 2020-10-03 US US17/062,545 patent/US11406611B2/en active Active
-
2025
- 2025-07-31 FI FIC20253004C patent/FIC20253004I1/fi unknown
- 2025-07-31 LT LTPA2025529C patent/LTPA2025529I1/lt unknown
- 2025-08-01 NO NO2025035C patent/NO2025035I1/no unknown
- 2025-08-05 FR FR25C1031C patent/FR25C1031I1/fr active Active
- 2025-08-13 HU HUS2500033C patent/HUS2500033I1/hu unknown
- 2025-08-13 NL NL301338C patent/NL301338I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ724057A (en) | Treatment of intrahepatic cholestatic diseases | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| EA201790528A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| IL272444A (en) | Compounds, their salts and methods for treating diseases | |
| PH12016501457B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| EP3481402A4 (en) | CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE | |
| NZ724740A (en) | Treatment of nafld and nash | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| EP3484504A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE | |
| MX2016009753A (es) | Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud. | |
| EA201691421A1 (ru) | Гетероарилы и их применение | |
| CY1122264T1 (el) | Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων | |
| MX2017009417A (es) | Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas. | |
| EP3268007A4 (en) | Compositions and therapeutic methods for the treatment of complement-associated diseases | |
| EP3231436A4 (en) | Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient | |
| MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
| EA201690284A1 (ru) | Композиции и терапевтические способы для ускоренного регресса бляшки | |
| EP3394047A4 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| EP3156055A4 (en) | Pharmaceutical composition for preventing or treating muscular weakness-related diseases, containing butylpyridinium or derivative thereof | |
| EP3275450A4 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis | |
| NZ730816A (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| EP3169405A4 (en) | Methods, compounds, and compositions for the treatment of musculoskeletal diseases | |
| LT3463328T (lt) | Seladelparas pirminiam tulžies cholangitui gydyti | |
| EP3119388A4 (en) | Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders | |
| DK3362056T3 (da) | Aminothiolesterforbindelser eller farmaceutisk acceptable salte deraf, til anvendelse ved behandling af cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2020 BY CPA GLOBAL Effective date: 20190201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2021 BY CPA GLOBAL Effective date: 20200227 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2022 BY CPA GLOBAL Effective date: 20210204 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2023 BY CPA GLOBAL Effective date: 20220204 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2024 BY CPA GLOBAL Effective date: 20230203 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250130 |